A previous study identified TWF2 as a prognostic biomarker in ccRCC via genome‐wide CpG methylation profiling.[21] However, its functional role and mechanistic contributions to drug resistance and tumor progression remain to be elucidated. This evidence concerns the gene TWF2 and nonpapillary renal cell carcinoma.